Robert F. Williamson III Purchases 22,192 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) Stock

Perspective Therapeutics, Inc. (NYSE:CATX) Director Robert F. Williamson III purchased 22,192 shares of Perspective Therapeutics stock in a transaction on Friday, March 28th. The shares were acquired at an average price of $2.27 per share, for a total transaction of $50,375.84. Following the completion of the transaction, the director now directly owns 70,837 shares of the company’s stock, valued at approximately $160,799.99. The trade was a 45.62 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Perspective Therapeutics Stock Performance

Shares of Perspective Therapeutics stock opened at $2.05 on Thursday. The business has a 50 day moving average of $2.85 and a 200 day moving average of $6.07. Perspective Therapeutics, Inc. has a 52 week low of $1.90 and a 52 week high of $19.05.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in CATX. FMR LLC boosted its stake in shares of Perspective Therapeutics by 3,994.9% during the 3rd quarter. FMR LLC now owns 5,504,822 shares of the company’s stock valued at $73,489,000 after purchasing an additional 5,370,392 shares in the last quarter. Millennium Management LLC bought a new stake in Perspective Therapeutics during the 4th quarter valued at approximately $4,132,000. State Street Corp grew its holdings in shares of Perspective Therapeutics by 119.6% during the 3rd quarter. State Street Corp now owns 2,190,239 shares of the company’s stock worth $29,240,000 after acquiring an additional 1,192,812 shares during the period. Octagon Capital Advisors LP raised its position in shares of Perspective Therapeutics by 62.1% in the 4th quarter. Octagon Capital Advisors LP now owns 2,304,752 shares of the company’s stock worth $7,352,000 after acquiring an additional 882,528 shares in the last quarter. Finally, Affinity Asset Advisors LLC lifted its stake in shares of Perspective Therapeutics by 160.0% in the 4th quarter. Affinity Asset Advisors LLC now owns 1,300,000 shares of the company’s stock valued at $4,147,000 after purchasing an additional 800,000 shares during the period. 54.66% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

CATX has been the topic of several recent research reports. Wedbush reaffirmed an “outperform” rating and set a $11.00 target price on shares of Perspective Therapeutics in a report on Wednesday, March 26th. Scotiabank started coverage on Perspective Therapeutics in a research note on Friday, March 7th. They set a “sector outperform” rating and a $15.00 price objective on the stock. Royal Bank of Canada lowered their target price on Perspective Therapeutics from $16.00 to $15.00 and set an “outperform” rating for the company in a research note on Thursday, March 27th. Brookline Capital Management upgraded Perspective Therapeutics to a “strong-buy” rating in a research report on Monday, March 10th. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Perspective Therapeutics in a research report on Monday. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $14.44.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.